Physician profile
Vinay Acharya
NPI 1720465743
$5,828.30
in general payments reported to CMS, 2019-2025
28 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $244 · 2021: $1,270 · 2022: $1,041 · 2023: $1,161 · 2024: $1,063 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261 · Education: $12.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,260.71 |
| Education | $12.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $869.63 | 2020-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $623.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.92 | 2020-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $563.49 | 2020-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $558.83 | 2020-2025 | Jynarque |
| Vifor Pharma, INC. | $445.17 | 2020-2024 | Veltassa |
| Horizon Therapeutics Plc | $323.98 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $295.49 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $219.26 | 2021-2025 | Vafseo |
| Glaxosmithkline, LLC. | $181.82 | 2021-2023 | Benlysta |
| Cormedix INC. | $158.43 | 2024-2025 | Defencath, Defencath |
| Novo Nordisk INC | $125.28 | 2022-2025 | Rybelsus, Ozempic |
| Travere Therapeutics, INC. | $123.98 | 2023 | |
| Aurinia Pharma U.S., INC. | $118.45 | 2021-2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $91.86 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.58 | 2023-2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $77.40 | 2021 | |
| Ani Pharmaceuticals, INC. | $66.01 | 2022-2023 | Purified Cortrophin Gel |
| Ardelyx, INC. | $65.49 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.23 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $39.91 | 2022 | |
| Genentech USA, INC. | $27.40 | 2025 | Gazyva |
| Renalytix Ai, INC. | $23.47 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $21.49 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $18.58 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.42 | 2022 | |
| Lilly USA, LLC | $15.10 | 2025 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Acharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.